The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Assessing the feasibility and cost-effectiveness of all oral adjuvant chemotherapy (cyclophosphamide, methotrexate, capecitabine) in high-risk hormone receptor positive breast cancer.
 
Abiola Falilat Ibraheem
Speakers' Bureau - Lilly
 
VK Gadi
Stock and Other Ownership Interests - 3rdEyeBio; Emerging Markets Cancer Ignition Fund; New Equilibrium Biosciences; Novilla; Phoenix Molecular Designs; Sengine precision medicine; Tahoma Therapeutics
Consulting or Advisory Role - AstraZeneca; Gilead Sciences; Hologic; Puma Biotechnology; Seagen/Pfizer; Stemline Therapeutics
Speakers' Bureau - Hologic; Puma Biotechnology; Seagen; Stemline Therapeutics
Research Funding - Agendia (Inst); Illumina; Tizona Therapeutics, Inc.
Travel, Accommodations, Expenses - Genentech/Roche; Puma Biotechnology; Seagen
 
Kent Hoskins
Employment - Lilly (I)
Research Funding - Abbvie (Inst); Genentech (Inst); Merck Sharp & Dohme (Inst); Novartis Pharmaceuticals UK Ltd. (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Agendia
Other Relationship - Agendia
 
Amina Chaudhry
No Relationships to Disclose